Anesiva, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) to expand the indication for Zingo(TM) to treat adults' pain associated with blood draws. Previously, Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system was only approved to treat the pain caused by peripheral IV insertions and blood draws in children aging 3-18 years.

As announced in November of last year, Anesiva ceased Zingo commercial activities to focus efforts on the development of Adlea(TM). This non-opioid, long-acting analgesic drug candidate was designed to mange the acute pain that follows orthopedic surgeries. Anesiva has intentions to license Zingo as well as the underlying drug delivery technology and intellectual property.